Rukobia 600 Mg 600 mg Prolonged-release tablets
PDF Leaflet Revision Date: 12 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of heavily treatment-experienced adults with multidrug resistant HIV-1.
Dosage (summary)
600 mg orally twice daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; likely secreted in breast milk.
Key Drug Interactions
- Strong CYP3A inducers
- Elbasvir/Grazoprevir
- Statins (OATP1B1/3 substrates)
Contraindications
- Hypersensitivity to fostemsavir
- Strong CYP3A inducers
Common side effects
- Insomnia
- Headache
- Dizziness
- Diarrhoea
- Nausea
- Rash
Counselling Points
- Take with or without food
- Do not chew or crush tablets
- Monitor for signs of opportunistic infections
Serious warnings
- QTc prolongation
- Immune Reconstitution Syndrome
Important Disclaimer
The Rukobia 600 Mg 600 mg Prolonged-release tablets professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
